vida: extract claims from 2026-04-24-qeadan-addiction-glp1-oud-aud-real-world

- Source: inbox/queue/2026-04-24-qeadan-addiction-glp1-oud-aud-real-world.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -46,3 +46,10 @@ Phase 2 RCT (n=48, 9 weeks) showed dose-dependent effects on alcohol use disorde
 **Source:** eClinicalMedicine (Lancet) 2025 systematic review and meta-analysis
 
 Meta-analysis of 14 studies (n=5,262,278) shows pooled AUDIT score reduction of −7.81 points (95% CI −9.02 to −6.60), which is clinically meaningful (moves patients from hazardous to non-hazardous drinking). Pooled observational studies show HR 0.64 (95% CI 0.59–0.69) for alcohol-related events — 36% lower rate. Individual RCTs with semaglutide show significant effects, though pooled RCT analysis is non-significant due to heterogeneity (I²=87.5%) and small-sample pooling. Semaglutide and liraglutide showed strongest and most consistent reductions across studies.
+
+
+## Extending Evidence
+
+**Source:** Qeadan F et al., Addiction 2025
+
+Qeadan et al. (2025) retrospective cohort study of 1.3M patients across 136 US health systems found GLP-1 RA prescriptions associated with 40% lower opioid overdose rates (IRR 0.60, 95% CI 0.43-0.83) in OUD cohort and 50% lower alcohol intoxication rates (IRR 0.50, 95% CI 0.40-0.63) in AUD cohort over 24-month follow-up. Effects consistent across T2DM, obesity, and combined subgroups. This is the largest-scale human data on GLP-1 for opioid outcomes, though observational design creates substantial healthy user bias concerns (patients receiving GLP-1 are more healthcare-engaged, financially able, and motivated). The consistency across subgroups (whether prescribed for diabetes or obesity) reduces some confounding concern. Published in Addiction (Wiley) with formal commentary noting need for prospective RCTs.

domains/health/semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct.m
 scope: causal
 sourcer: Hendershot CS et al.
 supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
-related: ["hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial"]
+related: ["hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression"]
 ---
 
 # Semaglutide produces large-effect-size reductions in alcohol consumption and craving through VTA dopamine reward circuit suppression
@@ -24,3 +24,10 @@ A 9-week double-blind RCT (n=48) demonstrated that semaglutide produces clinical
 **Source:** eClinicalMedicine (Lancet) 2025 systematic review
 
 Meta-analysis confirms semaglutide as best-performing agent for alcohol reduction across 14 studies. The −7.81 point AUDIT reduction represents movement from hazardous to non-hazardous drinking levels. Individual semaglutide RCTs (including Hendershot 2025) each show significant effects, with reductions in drinking days, units per drinking day, and cravings.
+
+
+## Supporting Evidence
+
+**Source:** Qeadan F et al., Addiction 2025
+
+Real-world observational data from 817,309 AUD patients (5,621 with GLP-1 RA) shows 50% lower alcohol intoxication rates (IRR 0.50, 95% CI 0.40-0.63) over 24 months, consistent with Hendershot RCT findings. Effect maintained across T2DM (IRR 0.51), obesity (IRR 0.58), and combined conditions (IRR 0.58) subgroups. Provides population-scale corroboration of the VTA dopamine mechanism hypothesis, though observational confounding limits causal inference.

inbox/archive/health/2026-04-24-qeadan-addiction-glp1-oud-aud-real-world.md

@@ -7,9 +7,12 @@ date: 2025-02-01
 domain: health
 secondary_domains: []
 format: peer-reviewed study
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-24
 priority: high
 tags: [glp-1, GIP, semaglutide, opioid-use-disorder, alcohol-use-disorder, AUD, OUD, addiction, real-world-data, observational, reward-circuit]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content